Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
43 hedge funds and large institutions have $9.16M invested in Repros Therapeutics Inc. in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 8 closing their positions.
1,470% more call options, than puts
Call options by funds: $675K | Put options by funds: $43K
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
7% less funds holding
Funds holding: 46 → 43 (-3)
37% less capital invested
Capital invested by funds: $14.5M → $9.16M (-$5.34M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$200K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$125K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$89.3K |
| 4 |
Renaissance Technologies
New York
|
+$85.7K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$44.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAI
General American Investors
New York
|
-$211K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$133K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$129K |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$96K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$40K |
RPRX Hedge Fund Activity: Q4 2016 in Review
43 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q4 2016, worth a combined $9.16M — down 37% from $14.5M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RPRX and 5 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 13 added.
The largest buyer was Sphera Funds Management, adding an estimated $200K. The largest seller was General American Investors, cutting an estimated $211K.
- 43 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q4 2016, down from 46 in Q3 2016.
- Funds reported $9.16M of Repros Therapeutics Inc. stock for Q4 2016, down 37% quarter-over-quarter.
- 5 funds opened new Repros Therapeutics Inc. positions in Q4 2016 and 8 closed out, a net change of -3 holders.
- The largest Repros Therapeutics Inc. buyer in Q4 2016 was Sphera Funds Management, an estimated $200K added.
- The largest Repros Therapeutics Inc. seller in Q4 2016 was General American Investors, an estimated $211K sold.
Based on aggregated 13F filings for Q4 2016.